-+ 0.00%
-+ 0.00%
-+ 0.00%

Why Centene Doubters Were Wrong Before A 96% Gain

Simply Wall St·11/14/2026 00:41:31
Listen to the news

If you only glanced at headlines about Medicaid funding worries and shrinking ACA membership, Centene might have looked like a value trap, not a wealth creator. For Centene shareholders, the return over the past year was 95.9%, including dividends. If you had been weighing those early 2025 margin concerns and mixed analyst targets before buying, how should you now think about a business that paired such gains with persistent policy and cost risks?

The easy part of this move is behind Centene. Zero in on 32 high quality undervalued stocks for companies trading below our estimates.

The Two Stories Centene Investors Were Weighing

The shares cost US$36.09 at the start of the period, and Centene investors had to choose between two very different stories about what came next.

The bullish narrative saw Medicare and Medicaid expansion as a long runway, with a Fair Value of US$70 that reflected what supporters thought the stock was worth if long term policy support and digital cost controls held.

The more cautious script pointed to a Fair Value of US$33.94 based on assumptions of 7.0% annual revenue growth and profit margins drifting to 1.1% as policy reform, medical costs and specialty drugs weighed on earnings.

NYSE:CNC 1-Year Stock Price Chart
NYSE:CNC 1-Year Stock Price Chart

What The Results Changed For The Centene Story

Centene’s Q3 2026 report showed revenue of US$45.4b and a loss of US$71m, an improvement from the much larger loss a year earlier as net margin moved from a deeply negative 14.6% to a slight 0.2% loss. That shift supported the optimistic case on margin repair, although profitability was still not proven, which kept the cautious script alive.

The clear hinge here was the path of net margin. When you evaluate another insurer, check not only whether revenue changes, but also whether losses narrow and the margin line moves toward the level implied by a more optimistic interpretation of the results.

What Centene's Run Up Now Asks You To Believe

Centene now trades at US$71.27, after a 95.9% gain over the past year. The bearish analyst Narrative on Simply Wall St places its Fair Value below that level, on the view that current guidance already bakes in much of the good news.

At this price you are effectively assuming Centene can convert AI driven cost work and repriced contracts into steady margins. The open question is how that assumption holds up if Medicaid membership pressure and quality score headwinds play out as this Narrative describes.

"The numbers suggest that Centene’s share price already reflects a fairly valued, bullish case in which current guidance on earnings, risk adjustment settlements, Medicaid rate yields and PDP profitability is largely delivered and sustained over time."

One Narrative has put a figure on that disagreement. → See the Narrative with its lower Fair Value, assumptions and all

Before The Next Story Makes Headlines

What if your next investment idea came before the headlines? Go straight to the companies whose prices and our estimates still disagree. Three places to start, with the names waiting behind the link.

  • Company 1 - 48% below our estimate - sells accelerated computing hardware and software that large cloud providers rapidly adopt.
  • Company 2 - 34% below our estimate - connects subscription software and AI workloads to expanding shared cloud infrastructure capacity.
  • Company 3 - 39% below our estimate - wins integrated subsea engineering projects that speed tiebacks and secure long-duration service contracts.

Those are three of them. See the full list of 24 financially solid companies →